UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation

The American journal of cardiology, 2013-08, Vol.112 (4), p.509-512

2013

Volltextzugriff (PDF)

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation: An Observational Study From a Cohort of Matched Users

Clinical therapeutics, 2015-03, Vol.37 (3), p.554-562

2015

Volltextzugriff (PDF)

Real-world EGFR testing patterns among U.S. patients with advanced NSCLC

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.298-298

2021

Volltextzugriff (PDF)

Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review

American health & drug benefits, 2014-04, Vol.7 (2), p.87-93

2014

Volltextzugriff (PDF)

PP01.68 Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e32-e32

2024

Volltextzugriff (PDF)

Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

Advances in therapy, 2022-07, Vol.39 (7), p.3347-3360

2022

Volltextzugriff (PDF)

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6638-6638

2023

Volltextzugriff (PDF)

HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy

Journal of the National Comprehensive Cancer Network, 2022-03, Vol.20 (3.5), p.HSR22-173

2022

Volltextzugriff (PDF)

Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease

Journal of medical economics, 2012, Vol.15 (1), p.45-52

2012

Volltextzugriff (PDF)

Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis

Clinical therapeutics, 2019-06, Vol.41 (6), p.1080-1089.e5

2019

Volltextzugriff (PDF)

Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer

Journal of medical economics, 2022-12, Vol.25 (1), p.457-468

2022

Volltextzugriff (PDF)

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer

Journal of managed care & specialty pharmacy, 2024-09, p.1-12

2024

Volltextzugriff (PDF)

Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review

Journal of medical economics, 2011, Vol.14 (4), p.397-402

2011

Volltextzugriff (PDF)

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

Journal of medical economics, 2024, Vol.27 (1), p.219-229

2024

Volltextzugriff (PDF)

Disparities in Lung Cancer: A Targeted Literature Review Examining Lung Cancer Screening, Diagnosis, Treatment, and Survival Outcomes in the United States

Journal of racial and ethnic health disparities, 2024-06, Vol.11 (3), p.1489-1500

2024

Volltextzugriff (PDF)

P-058 Crohn’s Disease Patients with Early Biologic Treatment Versus Late Biologic Treatment: Comparison of Patient Response to Therapy and Healthcare Costs

Inflammatory bowel diseases, 2013-12, Vol.19, p.S50-S51

2013

Volltextzugriff (PDF)

Caregiver Assistance Among Medicare Beneficiaries With Atrial Fibrillation and Factors Associated With Anticoagulant Treatment

The American journal of geriatric pharmacotherapy, 2012-10, Vol.10 (5), p.273-283

2012

Volltextzugriff (PDF)

Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis

PharmacoEconomics - open, 2023-07, Vol.7 (4), p.617-626

2023

Volltextzugriff (PDF)

Abstract 136: Non-Adherence to Anticoagulant Therapy Among Employed and Unemployed Patients With Venous Thromboembolism

Circulation Cardiovascular quality and outcomes, 2013-05, Vol.6 (suppl_1)

2013

Volltextzugriff (PDF)

Infliximab Dosing Patterns Among Individuals with Crohnʼs Disease: Results from a Mid-Atlantic Healthplan: 1491

The American journal of gastroenterology, 2012-10, Vol.107, p.S596

2012

Volltextzugriff (PDF)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Advances in therapy, 2015-03, Vol.32 (3), p.216-227

2015

Volltextzugriff (PDF)

Corrigendum to ‘Effects of Rivaroxaban versus Warfarin on Hospitalization Days and other Health Care Resource Utilization in Patients with Nonvalvular Atrial Fibrillation: an Observational Study from a Cohort of Matched Users’: Clin Ther 2015;37:554-62

Clinical therapeutics, 2015-08, Vol.37 (8), p.1870-1871

2015

Volltextzugriff (PDF)

Abstract 155: Prevalence of Self-Reported Risk Factors for Myocardial Infarction Among Patients With Venous Thromboembolism

Circulation Cardiovascular quality and outcomes, 2013-05, Vol.6 (suppl_1)

2013

Volltextzugriff (PDF)

Corrigendum to ‘Effects of Rivaroxaban versus Warfarin on Hospitalization Days and other Health Care Resource Utilization in Patients with Nonvalvular Atrial Fibrillation: an Observational Study from a Cohort of Matched Users’

Clinical therapeutics, 2015-08, Vol.37 (8), p.1870-1871

2015

Volltextzugriff (PDF)

Assessment of Infliximab Utilization Among Patients with Inflammatory Bowel Disease Across Different Sites of Care: 1446

The American journal of gastroenterology, 2012-10, Vol.107, p.S576

2012

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation

Effects of Rivaroxaban Versus Warfarin on Hospitalization Days and Other Health Care Resource Utilization in Patients With Nonvalvular Atrial Fibrillation: An Observational Study From a Cohort of Matched Users

Real-world EGFR testing patterns among U.S. patients with advanced NSCLC

Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review

PP01.68 Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy

Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC)

HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy

Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease

Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis

Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer

Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review

Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type

Disparities in Lung Cancer: A Targeted Literature Review Examining Lung Cancer Screening, Diagnosis, Treatment, and Survival Outcomes in the United States

P-058 Crohn’s Disease Patients with Early Biologic Treatment Versus Late Biologic Treatment: Comparison of Patient Response to Therapy and Healthcare Costs

Caregiver Assistance Among Medicare Beneficiaries With Atrial Fibrillation and Factors Associated With Anticoagulant Treatment

Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis

Abstract 136: Non-Adherence to Anticoagulant Therapy Among Employed and Unemployed Patients With Venous Thromboembolism

Infliximab Dosing Patterns Among Individuals with Crohnʼs Disease: Results from a Mid-Atlantic Healthplan: 1491

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Corrigendum to ‘Effects of Rivaroxaban versus Warfarin on Hospitalization Days and other Health Care Resource Utilization in Patients with Nonvalvular Atrial Fibrillation: an Observational Study from a Cohort of Matched Users’: Clin Ther 2015;37:554-62

Abstract 155: Prevalence of Self-Reported Risk Factors for Myocardial Infarction Among Patients With Venous Thromboembolism

Corrigendum to ‘Effects of Rivaroxaban versus Warfarin on Hospitalization Days and other Health Care Resource Utilization in Patients with Nonvalvular Atrial Fibrillation: an Observational Study from a Cohort of Matched Users’

Assessment of Infliximab Utilization Among Patients with Inflammatory Bowel Disease Across Different Sites of Care: 1446

Suchergebnisse filtern